Featuring perspectives from Dr Rachel N Grisham, including the following topics:

• Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)
• Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)
• Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)
• Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)

CME information and select publications